Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

EVERSANA® partnership for KidneyIntelX

May 25, 2023
RNS Number : 5773A Renalytix PLC 25 May 2023     Renalytix plc    ("Renalytix" or the "Company")   Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes   Model expected to accelerate deployment of

Expansion of insurance coverage for KidneyIntelX

May 22, 2023
RNS Number : 1093A Renalytix PLC 22 May 2023     Renalytix plc    ("Renalytix" or the "Company")   Expansion of insurance coverage for KidneyIntelX TM   LONDON and SALT LAKE CITY , May 22, 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX) reports the expansion of insurance coverage for KidneyIntelX with

Notice of GM and Posting of Circular

May 11, 2023
RNS Number : 0238Z Renalytix PLC 11 May 2023     Renalytix plc    ("Renalytix" or the "Company")   Notice of General Meeting and Posting of Circular   LONDON and SALT LAKE CITY , May 11, 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX) announces that a circular containing a notice convening a General

Real-World Evidence Shows KidneyIntelX™ Utility

April 19, 2023
RNS Number : 6476W Renalytix PLC 19 April 2023     Renalytix plc    ("Renalytix" or the "Company")   New Published Real-World Evidence Shows KidneyIntelX™ Utility   Real-World Utility Data Demonstrates KidneyIntelX Optimizes Clinical Management in Early-Stage Chronic Kidney Disease Across Multiple

Positive Data Release at NKF Conference

April 12, 2023
RNS Number : 8895V Renalytix PLC 12 April 2023   Renalytix plc    ("Renalytix" or the "Company")   Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting   In a clinical decision effectiveness study, KidneyIntelX

Half-year Report

March 30, 2023
RNS Number : 7000U Renalytix PLC 30 March 2023       Renalytix plc ("Renalytix" or the "Company")   Half Year Report   LONDON and SALT LAKE CITY , March 30, 2023   -   Renalytix plc (NASDAQ: RNLX) (LSE: RENX), reports its financial results for the six months ended December 31, 2022.

Business Update - Replacement

March 27, 2023
RNS Number : 3435U Renalytix PLC 27 March 2023     The following amendment has been made to the 'Business Update'   announcement released today, 27 March 2023 at 0700 under RNS No 2296U.   The real-world evidence data published in the   Journal of Primary Care Community Health   was published in

Business Update

March 27, 2023
RNS Number : 2296U Renalytix PLC 27 March 2023   Renalytix plc    ("Renalytix" or the "Company")   Business Update   LONDON and SALT LAKE CITY , March 27, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) provides the following business update.   Renalytix has further expanded its insurance coverage

Notice of Results

March 22, 2023
RNS Number : 7566T Renalytix PLC 22 March 2023       Renalytix plc    ("Renalytix" or the "Company")   Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30   LONDON and SALT LAKE CITY , March 22, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today

Second Price Monitoring Extn

March 21, 2023
RNS Number : 7502T Renalytix PLC 21 March 2023   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this
Displaying 111 - 120 of 357